USPTO serial 78871312
I-BUDE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- DE JONGE, KATHLEEN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with I-BUDE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Frances Love
Mary Frances Love Law Office of Mary F. Love, Esq.3509 Connecticut Ave., N.W.PMB 130Washington, DC 20008Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and medicinal preparations and substances for the prevention and treatment of diseases and disorders of the respiratory system including asthma, chronic obstructive pulmonary disease (COPD), breathlessness, cystic fibrosis, pulmonary hypertension and other respiratory diseases and treatment preparations therefor that can be administered to a patient through absorption through the lung; pharmaceutical preparations, namely, preparations for the prevention and treatment of cancers; pharmaceutical preparations, namely, platelet stimulating factors; pharmaceutical cardiovascular preparations; pharmaceutical preparations for the treatment of cardiovascular disease, urological disorders, gastrointestinal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, obesity and respiratory diseases, fungal disorders; pharmaceutical preparations, namely, anti-inflammatory analgesics; pharmaceutical preparations, namely, cholesterol reducers, smoking cessation preparations, medicated tissue and skin repair preparations; pharmaceutical preparations for the treatment of diabetes, cancer; pharmaceutical preparations comprising protein kinase or phosphatase for use in the treatment of cancer and Parkinson's disease; pharmaceutical preparations affecting signal transduction pathways for use in the treatment of inflammatory diseases, autoimmune diseases, and psychiatric diseases; pharmaceutical preparations for the prevention and/or treatment of cancer, carcinomas and sarcomas; pharmaceutical preparations for the prevention and/or treatment of tumors of any description; pharmaceutical preparations for the treatment of pains, fever, angina, otorhinolaryngology, gastric and liver illnesses, heart illnesses, arterial and venous illnesses, rheumatic illnesses; analgesics; frostbite salve for pharmaceutical purposes; hemorrhoid treatment preparations; pharmaceutical preparations for the treatment of headaches; bath salts for medical purposes; medicated mouthwashes; herbal mud packs for therapeutic purposes; tranquilizers; sedatives; tobacco free cigarettes for medical purposes; medicines for alleviating constipation; contraceptive preparations; radiological contrast substances for medical purposes, namely, contrast media for in-vivo imaging; corn remedies, namely, corn creams, corn pads and corn plasters; cotton for medical purposes; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of pain, fever, angina, otorhinolaryngology, gastric and liver illnesses, heart illnesses, arterial and venous illnesses, rheumatic illnesses; mineral water for medical purposes; pharmaceutical preparations for the treatment of tremors, smooth muscle disorders, headaches, wrinkles, hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments, or bone; pharmaceutical preparations for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labor pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical preparations for the treatment of muscle dystonias, nerve disorders, spasmodic striated, smooth or cardiac muscles; pharmaceutical preparations for the treatment of cerebral palsy; pharmaceutical preparations and substances, namely anti-infective, anti-bacterials, antibiotics, antivirals, antidiabetic preparations, cardiovascular preparations, hemostatic agents; pharmaceutical preparations and substances for the treatment of cancer, HIV, obesity and respiratory and urologic disorders and diseases; pharmaceutical preparations and substances for the treatment of acute ischemic stroke and traumatic brain injury (TBI); cerebral vasodilators; prescription pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the respiratory system, peripheral nervous system, cardiovascular system, gastro-intestinal system; prescription pharmaceutical preparations and substances for use in pain control; anesthetics for surgical and non-surgical use; pharmaceutical preparations for use in oncology for the prevention and treatment of disorders; prescription pharmaceutical preparations and substances for the treatment and prevention of diabetes; vaccines; dietetic substances adapted for medical purposes; nebules for inhalation, namely liquid drug formulations designed for delivery to the patient via a nebuliser for administration to the lung | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 18, 2011 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 17, 2011 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 22, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 21, 2010 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 17, 2010 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 17, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 3, 2010 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 1, 2010 | PAPER RECEIVED | — | |
| Dec 22, 2009 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 15, 2009 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 15, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2009 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 17, 2009 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 28, 2009 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 28, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 20, 2008 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 20, 2008 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 20, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2008 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 17, 2008 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 17, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 18, 2007 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 25, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 5, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 21, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 21, 2007 | ALIE | ASSIGNED TO LIE | — |
| Jul 7, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2007 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 6, 2007 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 28, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 27, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 27, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 28, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2006 | NWAP | NEW APPLICATION ENTERED | — |